COMMUNIQUÉS West-GlobeNewswire

Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies
16/07/2026
Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilities at ARC Oxford, a [...]
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
16/07/2026
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both [...]
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
16/07/2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, [...]
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
16/07/2026
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety [...]
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
16/07/2026
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the [...]
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET [...]
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026
The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE [...]
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
16/07/2026
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end viral vector [...]
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
16/07/2026
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 16, 2026 ( [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/07/2026
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07/2026
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine [...]
A breakthrough in coronary bypass surgery: AMT Medical’s SAFE-CAB results published in The Journal of Thoracic and Cardiovascular Surgery
16/07/2026
Video: How does AMT’S ELANA® system work? The first suture-less, beating-heart bypass connection, shown to be safe with promising early effectiveness in a peer-reviewed clinical trial. AMT Medical reports one-year [...]
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- BienRaíz today announced the launch of BienRaíz Magnesium Glycinate Supplement, a daily magnesium glycinate supplement formulated with 240 mg elemental magnesium per serving. [...]
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026
Sales Highlights (unaudited): Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp) 2H FY26 sales AUD$3.5 million up 7% on pcp 4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 [...]
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026
www.arlettapharmasolutions.com FDA endorses key elements of the proposed Phase 2 dose-ranging study and openness to a single pivotal Phase 3 study to support a future NDA Amsterdam, the Netherlands, 16 July 2026 — [...]
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]

Pages